ストックスクリーナーアプリを入手
0.257
5.24%
-0.0142
プレマーケット:
.26
0.003
+1.17%
前日終値:
$0.2712
開ける：
$0.27
24時間の取引高:
3.81M
Relative Volume:
0.41
時価総額：
$45.84M
収益：
-
当期純損益:
$-12.89M
株価収益率:
-0.1016
EPS:
-2.53
ネットキャッシュフロー:
$-11.95M
1週間 パフォーマンス:
+9.88%
1か月 パフォーマンス:
-47.55%
6か月 パフォーマンス:
-64.83%
1年 パフォーマンス:
-77.05%
1日の値動き範囲:
$0.257
$0.281
1週間の範囲:
$0.2223
$0.281
52週間の値動き範囲:
$0.1634
$2.3099
Plus Therapeutics Inc Stock (PSTV) Company Profile
Compare PSTV vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PSTV
Plus Therapeutics Inc
|
0.257 | 48.37M | 0 | -12.89M | -11.95M | -2.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Plus Therapeutics Inc Stock (PSTV) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-03 | 開始されました | Lake Street | Buy |
| 2025-09-03 | アップグレード | D. Boral Capital | Hold → Buy |
| 2025-03-17 | 開始されました | D. Boral Capital | Buy |
| 2021-01-25 | 開始されました | Ladenburg Thalmann | Buy |
| 2020-10-16 | 開始されました | Maxim Group | Buy |
Plus Therapeutics Inc (PSTV) 最新ニュース
Aug Decliners: Can Plus Therapeutics Inc stock double in the next yearQuarterly Risk Review & Capital Efficient Trading Techniques - baoquankhu1.vn
Aug EndMonth: What is MPWRs valuation compared to sectorStock Surge & Risk Controlled Swing Trade Alerts - baoquankhu1.vn
How Analyst Revisions Are Rewriting The Story For Plus Therapeutics (PSTV) - Yahoo Finance
Merger Talk: What is the dividend yield of Plus Therapeutics IncPortfolio Gains Summary & Real-Time Volume Analysis Alerts - baoquankhu1.vn
Market Rankings: Is Plus Therapeutics Inc stock undervalued right nowBond Market & Daily Entry Point Alerts - baoquankhu1.vn
Exit Recap: What is Atlas Lithium Corporations revenue forecastJuly 2025 Movers & AI Enhanced Execution Alerts - baoquankhu1.vn
Is Plus Therapeutics Inc. a top pick in the sectorQuarterly Risk Review & Free Technical Pattern Based Buy Signals - mfd.ru
Bond Watch: What is the cash position of LifeMD IncJuly 2025 Momentum & Weekly High Momentum Picks - baoquankhu1.vn
Published on: 2026-01-27 09:16:26 - baoquankhu1.vn
Institution Moves: Is Plus Therapeutics Inc on track to beat earningsTrade Signal Summary & Daily Entry Point Trade Alerts - baoquankhu1.vn
Price Action: Is Euroholdings Ltd. stock showing strong momentumJuly 2025 Recap & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
H.C. Wainwright lowers Plus Therapeutics stock price target on equity offering - Investing.com India
Maxim Group Maintains Plus Therapeutics(PSTV.US) With Buy Rating, Cuts Target Price to $1.5 - 富途牛牛
Plus Therapeutics secures $5.7M to support leptomeningeal metastases program - MSN
H.C. Wainwright Maintains Plus Therapeutics(PSTV.US) With Buy Rating, Cuts Target Price to $1 - 富途牛牛
Plus Therapeutics (PSTV) Sees Price Target Cut by HC Wainwright | PSTV Stock News - GuruFocus
Plus Therapeutics outlines 2026 goals for cancer treatments and diagnostics By Investing.com - Investing.com South Africa
Aug Mood: Is ABCL forming higher highs and higher lowsJuly 2025 Analyst Calls & Weekly Top Gainers Trade List - baoquankhu1.vn
Market Review: What dividend growth rate does Plus Therapeutics Inc offerWeekly Gains Summary & Precise Swing Trade Entry Alerts - baoquankhu1.vn
Plus Therapeutics, Inc. Provides Business Update on REYOBIQ Clinical Program and U.S. CNSide Commercialization - marketscreener.com
PSTV: $15M raise funds clinical and commercial growth; CNSIDE targets break-even by 2027 - TradingView — Track All Markets
Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, January 22, 2026 at 9:00 A.M. ET - Sahm
Plus Therapeutics Sets 2026 Milestones For REYOBIQ Clinical Program And CNSide Commercial Rollout - Nasdaq
Plus Therapeutics outlines 2026 goals for cancer treatments and diagnostics - Investing.com
PSTV Analyst Rating Update: Price Target Lowered to $4.00 | PSTV Stock News - GuruFocus
Plus Therapeutics Sharpens Focus on CNS Cancer Strategy - TipRanks
PSTV: 2026 focus: CNSide scale-up, REYOBIQ pivotal trial prep, and expanded payor coverage - TradingView
Plus Therapeutics Provides Business Update on REYOBIQ™ Clinical Program and U.S. CNSide® Commercialization - manilatimes.net
Plus Therapeutics, Inc. Updates Corporate Presentation on Cancer Radiotherapeutics - TradingView
Plus Therapeutics To Provide Business Update Today As Radiotherapeutic Pipeline Advances - Nasdaq
Plus Therapeutics To Provide Business Update On Thursday - TradingView
Plus Therapeutics, Inc. to Host Business Update and Conference Call on January 22, 2026 | PSTV Stock News - Quiver Quantitative
Plus Therapeutics to Provide Business Update and Host - GlobeNewswire
Investors get Plus Therapeutics business update in Jan. 22 webcast - Stock Titan
Should you avoid Plus Therapeutics Inc stock right now2025 Winners & Losers & Verified Momentum Stock Alerts - baoquankhu1.vn
Earnings Report: Will Plus Therapeutics Inc benefit from rising consumer demand2025 Market Overview & Stock Portfolio Risk Management - baoquankhu1.vn
Growth Value: Is Plus Therapeutics Inc a cyclical or defensive stockMarket Movement Recap & AI Enhanced Execution Alerts - baoquankhu1.vn
Aug Opening: Can Plus Therapeutics Inc reach all time highs this yearLayoff News & Real-Time Volume Triggers - baoquankhu1.vn
Plus Therapeutics completes underwritten public equity offering - TipRanks
Plus Therapeutics Signs Underwriting Agreement With Lake Street Capital Markets - TradingView — Track All Markets
Plus Therapeutics Inc enters underwriting agreement with Lake Street Capital Markets, LLCSEC filing - marketscreener.com
Plus Therapeutics IncOn Jan 13, Co Enters Underwriting Agreement With Lake Street Capital Markets, LlcSEC Filing - TradingView — Track All Markets
Whale Trades: Is UONE stock suitable for long term investingJuly 2025 Earnings & Fast Moving Stock Trade Plans - baoquankhu1.vn
Analyst Downgrade: Is UDR Inc in accumulation or distribution phaseJuly 2025 Intraday Action & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
Plus Therapeutics, Inc. (NASDAQ:PSTV) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Plus Therapeutics Announces Pricing of Upsized $15 Million Public Offering - Sahm
Plus Therapeutics stock plunges after pricing $15M units offering - MSN
Plus Therapeutics prices $15 million public offering at $0.38 per unit - Investing.com Nigeria
Plus Therapeutics Prices Public Offering, Raising $15 Million - Intellectia AI
Plus Therapeutics Spurs After-Hours Biotech Rally; Connect Biopharma And Elutia Also Advance - Nasdaq
Plus Therapeutics Secures National Coverage Agreement with Humana for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer - MSN
Plus Therapeutics Inc (PSTV) 財務データ
収益
当期純利益
現金流量
EPS
1.24%
0.19%
大文字化:
|
ボリューム (24 時間):